API Suppliers
US DMFs Filed
0
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
0
Europe
Canada
0
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
Details:
TNX-2900" (Oxytocin Magnesium) is an Oxytocin receptor Agonist Peptide drug candidate, which is currently being evaluated for the treatment of Prader-Willi syndrome.
Lead Product(s): Oxytocin,Magnesium
Therapeutic Area: Genetic Disease Product Name: TNX-2900
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 04, 2023
Details:
SFA-002 oral pill acts as down-regulating levels of pro-inflammatory cytokines involved in the pathogenesis of psoriasis including TNF-α, IL-23, IL-12, IL-17 and INF-γ, and down-regulating autoimmunity.
Lead Product(s): SFA-002,Vitamin D,Magnesium
Therapeutic Area: Dermatology Product Name: SFA-002
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 14, 2023
Details:
TNX-2900 (oxytocin) is believed to interrupt pain signals at the trigeminal ganglia by suppressing electrical impulses, a potentially different activity than drugs that just block CGRP. It is being investigayed for prader-willi syndrome.
Lead Product(s): Oxytocin,Magnesium
Therapeutic Area: Genetic Disease Product Name: TNX-2900
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2023
Details:
SFA002 is a new oral therapeutic agent for the treatment of mild-moderate psoriasis. SFA-002 is a potential multi-target and disease-modifying therapeutic that has demonstrated efficacy, safety and durability in Phase 1a studies.
Lead Product(s): SFA-002,Vitamin D,Magnesium
Therapeutic Area: Dermatology Product Name: SFA-002
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2023
Details:
TNX-1900 (intranasal potentiated oxytocin) is believed to interrupt pain signals at the trigeminal ganglia by suppressing electrical impulses, a potentially different activity than drugs that just block CGRP.
Lead Product(s): Oxytocin,Magnesium
Therapeutic Area: Neurology Product Name: TNX-1900
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2022
Details:
TNX-2900, Tonix’s proprietary potentiated intranasal oxytocin is in the pre-Investigational New Drug (IND) stage as a candidate for the treatment of Prader-Willi syndrome (PWS) and non-organic failure to thrive disease.
Lead Product(s): Oxytocin,Magnesium
Therapeutic Area: Nutrition and Weight Loss Product Name: TNX-2900
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2022
Details:
WHITNEY JOHNS ACTIVE (lepidium meyenii root extract) proven all-natural BPF Gold Citrus Bergamot SuperFruit™ formulation, has been clinically proven to increase NO by 73% and oxygen consumption by 24%, thereby enhancing physical performance and the benefits of exercise.
Lead Product(s): Lepidium Meyenii Root Extract,Choline,Magnesium
Therapeutic Area: Musculoskeletal Product Name: Active
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2022
Details:
Intranasal TNX-1900 (oxytocin) with magnesium demonstrated augmented craniofacial analgesia in an animal model enhanced effect of mg2+ is the core patented technology of TNX-1900 (oxytocin) for migraine.
Lead Product(s): Oxytocin,Magnesium
Therapeutic Area: Neurology Product Name: TNX-1900
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2022
Details:
Xywav (Calcium) is a lower-sodium oxybate approved by FDA for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy and for the treatment of idiopathic hypersomnia in adults.
Lead Product(s): Calcium,Magnesium,Potassium
Therapeutic Area: Sleep Product Name: Xywav
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2022
Details:
This FDA approval is based on the global Phase 3 double-blind, multicenter, placebo-controlled, randomized withdrawal study that demonstrated the efficacy and safety of Xywav for the treatment of idiopathic hypersomnia in adults.
Lead Product(s): Calcium,Magnesium,Potassium
Therapeutic Area: Sleep Product Name: Xywav
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 12, 2021
Details:
Results from the Phase 3, placebo-controlled, double-blind, randomized withdrawal study of Xywav in adults with idiopathic hypersomnia including an oral presentation of the correlation of the idiopathic hypersomnia severity scale score with other measures of sleep parameters.
Lead Product(s): Calcium,Magnesium,Potassium
Therapeutic Area: Sleep Product Name: Xywav
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2021
Details:
Xywav demonstrated highly statistically significant differences in median change in weekly number of cataplexy attacks and Epworth Sleepiness Scale scores compared to placebo.
Lead Product(s): Calcium,Magnesium,Potassium
Therapeutic Area: Sleep Product Name: Xywav
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2020
Details:
All patients were treated with Xywav during the open-label titration period and clinically meaningful improvements in the Epworth Sleepiness Scale (ESS) were observed.
Lead Product(s): Calcium,Magnesium,Potassium
Therapeutic Area: Sleep Product Name: Xywav
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2020